Insilico Produces COVID-19 Vaccine With Artificial Intelligence Support

COVID-19, which broke out in 2019 and caused a long-term pandemic and millions of people to die all over the world in a short time, is one of the most devastating diseases of recent years, according to many people. Although effective drugs have been developed for this virus in a short time, COVID-19 is still seriously showing its effects in many parts of the world at the moment.

With the rapid development of technology and artificial intelligence in recent years, the health sector has started to accelerate its efforts to benefit from the power of artificial intelligence. Hong-Kong-based pharmaceutical company Insilico Medicine has already It has already produced the first COVID-19 vaccine developed with the support of artificial intelligence.

Clinical testing has already begun in China

Insilico Medicine, whose founders are Canadian but based in Hong Kong, announced that they have produced the most effective and “near perfect” COVID-19 vaccine to date, with the support of an artificial intelligence model specially prepared for the health sector. Alex Zhavoronkov, the founder of Insilico, stated that they completed the laboratory tests, which normally take months, in just a few days thanks to artificial intelligence. “in determining which enzymes the drug will target” played a critical role and in the simulations made in the laboratory environment, it was determined that the drug was much more effective than expected.

Insilico’s new COVID-19 vaccine binds together enzymes in the virus, known as proteases, so that these enzymes cannot affect the human body. Former President of Oxford University, Dr. Peter Juni on Insilico’s new drug “I think the target of the drug is great. Because the targeted proteases are different from the proteases found in the human body and so it’s almost impossible for the drug to harm the body by targeting the wrong proteases.He stated that the drug can be effective and reliable.

While Insilico researchers refrained from explaining the artificial intelligence used in the production of this vaccine, they announced that the first clinical tests will begin with laboratories in China next Thursday.